Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fathers Too: Treating Paternal ADHD
NCT02675400Phase 4Completed
- Sponsor
- Seattle Children's
- Start
- Dec 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Seattle Children's. Primary endpoints: Clinical Global Impressions-Severity at 8 weeks, Conners Adult ADHD Rating Scale at 8 weeks and 3 more. Started Dec 2015; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02675400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02675400.